Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Lyell Immunopharma (LYEL) Return on Capital Employed: 2021-2025

Historic Return on Capital Employed for Lyell Immunopharma (LYEL) over the last 4 years, with Sep 2025 value amounting to -0.94%.

  • Lyell Immunopharma's Return on Capital Employed fell 58.00% to -0.94% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.94%, marking a year-over-year decrease of 58.00%. This contributed to the annual value of -0.63% for FY2024, which is 33.00% down from last year.
  • Latest data reveals that Lyell Immunopharma reported Return on Capital Employed of -0.94% as of Q3 2025, which was up 2.17% from -0.96% recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Return on Capital Employed ranged from a high of -0.18% in Q3 2021 and a low of -0.96% during Q2 2025.
  • Its 3-year average for Return on Capital Employed is -0.51%, with a median of -0.35% in 2024.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first grew by 1bps in 2023, then slumped by 61bps in 2025.
  • Quarterly analysis of 5 years shows Lyell Immunopharma's Return on Capital Employed stood at -0.19% in 2021, then declined by 1bps to -0.20% in 2022, then declined by 13bps to -0.33% in 2023, then plummeted by 38bps to -0.72% in 2024, then crashed by 58bps to -0.94% in 2025.
  • Its Return on Capital Employed was -0.94% in Q3 2025, compared to -0.96% in Q2 2025 and -0.86% in Q1 2025.